Ocuphire Pharma Receives PDUFA Fee Waiver for Nyxol New Drug Application from FDA

NDA Submission for Nyxol Eye Drops in First Indication on Track for Late 2022 FARMINGTON HILLS, Mich., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials